P-029 Impact of in-hospital delirium on outcomes of acute ischemic stroke

46% had left-sided disease (n=7), 33% had right-sided disease (n=5), and 20% had bilateral disease (n=3). The majority were male (n=10). Average age at the start of treatment was 1 year 5.5 months. A total of 66 treatments were performed, with a median of 4 per patient or 3.5 per involved eye. Of the 18 eyes treated, 12 (66%) initially had anterograde ophthalmic artery flow. Drug delivery was accomplished using direct ophthalmic catheterization (n=35), ICA balloon technique (n=18), ECA balloon technique (n=7), and via ECA branch catheterization (n=6). A flow reversal event was observed a total of 5 times (28% of eyes), each necessitating a change in drug delivery technique. All 5 events were in patients receiving multi-agent chemotherapy. These events occurred in 4 patients and involved 5 separate eyes, never more than once per eye. Flow reversal events were seen in both eyes (left=3, right=2). On average, events occurred between the third and fourth treatment (range 2 to 6). No correlation was found between reversal event and treatment technique. Conclusions Ophthalmic artery flow is variable in RB patients treated with IAC. Further, mid-treatment shifts between anterograde and retrograde ophthalmic artery filling are common and necessitate variation in delivery methods throughout a single treatment course. In our analysis all flow reversal events were associated with multi-agent chemotherapy (as opposed to Melphalan alone). Although the correlation was not statistically significant,our analysis is limited by power. Future investigation is necessary to elucidate the nature of these variations, such as if they are a direct response to the number of chemotherapy agents utilized. Regardless, interventionalists should be comfortable and prepared to use various techniques independent of a given patient’s treatment history. Disclosures M. Feldman: None. H. Grimaudo: None. S. Roth: None. H. Vance: None. A. Daniels: None. M. Froehler: 1; C; Genentech, Medtronic, Stryker, Microvention, and Penumbra. 2; C; Genentech, Medtronic, Stryker, Balt USA, Viz.ai, and Corindus.